Entrada Therapeutics (TRDA) EBITDA (2020 - 2026)

Entrada Therapeutics' EBITDA history runs 7 years deep, the most recent figure standing at -$42.3 million for Q1 2026.

• On a quarterly basis, EBITDA fell 94.14% year-over-year to -$42.3 million in Q1 2026; TTM through Mar 2026 was -$178.4 million, a 4443.01% decrease from a year earlier, with the FY2025 full-year figure at -$157.9 million, down 435.87% from the prior year.
• EBITDA held at -$42.3 million in Q1 2026 per TRDA's latest filing, from -$42.2 million in the prior quarter.
• Across five years, EBITDA topped out at $53.4 million in Q2 2024 and bottomed at -$47.1 million in Q3 2025.
• The 5-year median for EBITDA is -$21.8 million (2025), against an average of -$14.9 million.
• Across the five-year window, EBITDA jumped 465.28% in 2024 and sank 619.41% in 2025, its largest moves.
• Year by year, EBITDA stood at -$25.6 million in 2022, then surged by 119.18% to $4.9 million in 2023, then slumped by 219.61% to -$5.9 million in 2024, then sank by 619.41% to -$42.2 million in 2025, then fell by 0.23% to -$42.3 million in 2026.
• Per Business Quant, the three latest TRDA EBITDA figures stand at -$42.3 million (Q1 2026), -$42.2 million (Q4 2025), and -$47.1 million (Q3 2025).